Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Phase 2 Study ◽

A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial

Journal of Hematology & Oncology ◽

10.1186/1756-8722-6-41 ◽

2013 ◽

Vol 6 (1) ◽

Cited By ~ 24

Author(s):

Jian Hou ◽

Xin Du ◽

Jie Jin ◽

Zhen Cai ◽

Fangping Chen ◽

...

Keyword(s):

Multiple Myeloma ◽

Low Dose ◽

Chinese Patients ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

13 / An Open-label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

10.26226/morressier.5b3b802db1b87b000eceda02 ◽

2018 ◽

Author(s):

Fonseca Rafael

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Community Oncology ◽

Phase 2 Study ◽

An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.131 ◽

2018 ◽

Vol 18 ◽

pp. S240-S241

Author(s):

Rafael Fonseca ◽

Melissa Alsina ◽

Jesus Berdeja ◽

Stephen B. Heitner ◽

Christopher Morris ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Community Oncology ◽

Phase 2 Study ◽

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Case Medical Research ◽

10.31525/ct1-nct04287855 ◽

2020 ◽

Author(s):

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

International Journal of Hematology ◽

10.1007/s12185-019-02757-0 ◽

2019 ◽

Vol 111 (1) ◽

pp. 65-74 ◽

Cited By ~ 3

Author(s):

Kohmei Kubo ◽

Mitsuo Hori ◽

Kensuke Ohta ◽

Hiroshi Handa ◽

Kiyohiko Hatake ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Newly Diagnosed ◽

Open Label ◽

Phase 2 Study ◽

A multicenter, randomized, open-label, phase 2 study of carfilzomib with or without ARRY-520 (filanesib) in patients with advanced multiple myeloma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8612 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8612-8612 ◽

Author(s):

Jeffrey A. Zonder ◽

Noopur S. Raje ◽

Emma Catherine Scott ◽

Craig C. Hofmeister ◽

Nikoletta Lendvai ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.09.240 ◽

2019 ◽

Vol 19 (10) ◽

pp. e144

Author(s):

Ajai Chari ◽

Hartmut Goldschmidt ◽

shiyi yang ◽

Michele Kosh ◽

Maria Delioukina ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Multicenter Phase ◽

Phase 2 Study

Randomized, open-label, phase 2/3 study of daratumumab (DARA) with or without JNJ-63723283, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps8057 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS8057-TPS8057 ◽

Author(s):

Jan Van Droogenbroeck ◽

Philip Vlummens ◽

Noa Lavi ◽

Ka Lung Wu ◽

Jiayu Fu ◽

...

Keyword(s):

Multiple Myeloma ◽

Monoclonal Antibody ◽

Phase 2 ◽

Open Label ◽

An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2017.07.148 ◽

2017 ◽

Vol 17 ◽

pp. S333-S334 ◽

Author(s):

Meletios Dimopoulos ◽

Sebastian Grosicki ◽

Wiesław Jędrzejczak ◽

Hareth Nahi ◽

Astrid Gruber ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Newly Diagnosed ◽

Open Label ◽

Phase 2 Study ◽

9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71927-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 571 ◽

Author(s):

D. Siegel ◽

R. Vij ◽

K. Stewart ◽

G. Somlo ◽

A. Jakubowiak ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study